Download - Supplementary Fig.1

Transcript
Page 1: Supplementary Fig.1

Supplementary Fig.1

0.02.04.06.08.0

10.012.014.0

DAOY D458Med

Med8A NCB

miR-182

miR-183

Native expression

Re

lativ

e e

xpre

ssio

nra

tio v

s. H

KsR

NA

sa

0

10

20

30

40

50

60

70

pCMX 182K1 182K2 183K1 183K2

Re

lativ

e e

xpre

ssio

nra

tio v

s. p

CM

X

DA

OY

Med

8AR

ela

tive

exp

ress

ion

ratio

vs.

pC

MX

Stable overexpression

b

0

20

40

60

80

100

120

140

pCMX 182K1 182K2 183K1 183K2

D45

8 M

ed

Re

lativ

e e

xpre

ssio

nra

tio v

s. p

CM

X

012345678

pCMX 182K1 182K2 183K1 183K2

Page 2: Supplementary Fig.1

Supplementary Fig.1

0.0

0.3

0.6

0.9

1.2

1.5

siCtrl si182 siCtrl si183

Re

lativ

e e

xpre

ssio

nra

tio v

s. s

iCtr

lR

ela

tive

exp

ress

ion

ratio

vs.

siC

trl

Transient knockdown

DA

OY

Med

8Ac

0.00.20.40.60.81.01.21.41.6

siCtrl si182 siCtrl si183

Re

lativ

e e

xpre

ssio

nra

tio v

s. s

iCtr

l

D45

8 M

ed

0.0

0.3

0.6

0.9

1.2

1.5

siCtrl si182 siCtrl si183

Page 3: Supplementary Fig.1

Supplementary Fig.2

Page 4: Supplementary Fig.1

Supplementary Fig.3

Page 5: Supplementary Fig.1

Molecular subgroup

miR-182 miR-183 miR-96

Supplementary Fig.4

Page 6: Supplementary Fig.1

Supplementary Fig. 5

Page 7: Supplementary Fig.1

Transient knockdown

0.5

1.0

1.5

2.0

2.5

3.0

3.5

1 2 3 4 5 6 7

DAOY-siCtrlDAOY-si183

DAOY-si182

0.5

1.0

1.5

2.0

2.5

3.0

1 2 3 4 5 6 7

M8A-siCtrl

M8A-si183

M8A-si182

Day

Me

tab

olic

act

ivity

, ra

tio v

s. D

ay1

Me

tab

olic

act

ivity

, ra

tio v

s. D

ay1

0.0

1.0

2.0

3.04.0

5.0

6.0

7.0

8.0

1 2 3 4 5 6 7

DAOY-pCMX

DAOY-183K1

DAOY-183K2

0.0

1.0

2.0

3.04.0

5.0

6.0

7.0

8.0

1 2 3 4 5 6 7

DAOY-pCMX

DAOY-182K1

DAOY-182K2

0.51.01.52.02.53.03.54.04.55.0

1 2 3 4 5 6 7

M8A-pCMXM8A-183K1M8A-183K2

0.51.01.52.02.53.03.54.04.55.0

1 2 3 4 5 6 7

M8A-pCMXM8A-182K1

M8A-182K2

Stable overexpression

Day Day

Me

tab

olic

act

ivity

, ra

tio v

s. D

ay1

Me

tab

olic

act

ivity

, ra

tio v

s. D

ay1

DA

OY

Med

8A

*

*

**

Supplementary Fig. 6


Top Related